Tags : Collaboration

Pharma

Boehringer Ingelheim and MD Anderson Expand their Collaboration to Accelerate

Shots: Boehringer Ingelheim and MD Anderson expand their 2019 joint VRDC to explore new molecules from Boehringer Ingelheim’s KRAS and TRAILR2 portfolios for lung cancer, particularly NSCLC The joint research will continue for 5 additional years. The extended collaboration follows successful preclinical studies in GI cancers via joint VRDC The expanded agreement allows the partners […]Read More

Pharma

Merck KGaA Expand its Collaboration with NKMax to Evaluate the

Shots: The companies plan to conduct a P-I/IIa trial assessing the safety and anti-tumor activity of SNK01 + gemcitabine/carboplatin or gemcitabine/carboplatin + Erbitux (cetuximab) in patients with LA or mNSCLC after prior TKI therapy NKMax will sponsor the study while Merck KGaA will supply cetuximab (250 mg/m2, wq, IV) for P- I/IIa trial in NSCLC […]Read More

DigiHealth

Merck KGaA Selects PRA’s Remote Patient Monitoring Platform for Human

Shots: Merck KGaA selects PRA’s remote patient monitoring platform to work in combination with its HGH treatment system PRA’s remote patient monitoring platform will support Merck’s KGH system including its growlink (mobile app) and easypod connect (HCP platform) to monitor patient adherence, review injection history, and share information about the progress of patients with GHD […]Read More

Viewpoints

ViewPoints Interview: Eli Lilly’s Marie Schiller Shares Insight on the

In an interview with PharmaShots, Marie Schiller Vice President of Product Development for Connected Care and Insulins at Lilly shared her views on its collaboration with Welldoc to integrate Welldoc’s insulin management technology into Lilly’s connected insulin solutions. Shots: Lilly and Welldoc are teaming up to create a new version of Welldoc’s BlueStar app which will be […]Read More

Viewpoints

ViewPoints Interview: ALX Oncology’s Dr. Sophia Randolph Shares Insight on

In an interview with PharmaShot, Dr. Sophia Randolph, Chief Medical Officer of ALX Oncology shared her views on the ALX Oncology’s collaboration with Zymework for evaluating the combination with ALX148 and zanidatamab for patients with advanced HER2-expressing breast cancer and other HER2-expressing solid tumors. Shots: Zymeworks will conduct a P-Ib study to assess the safety […]Read More

Pharma

Genentech Signs an Exclusive License Agreement with X-Chem to Discover

Shots: X-Chem to receive an up front and is eligible to receive research, development and regulatory milestone along with royalties on sales of therapies resulting from the collaboration Genentech will lead further development and commercialization of any potential new therapies and retain exclusive rights to compounds derived from the collaboration. Additionally, Genentech get an exclusive […]Read More

Pharma

ImmunoGen Signs an Agreement with Huadong to Develop & Commercialize

Shots: ImmunoGen to receive $40M up front, ~$265M as development, regulatory & commercial milestones and is eligible to receive royalties on sales of mirvetuximab in Greater China and will retain all rights to mirvetuximab in the US & ROW The collaboration accelerates the development path for mirvetuximab in Greater China and expands Huadong’s oncology portfolio […]Read More